Polymorphism in the P-glycoprotein drug transporter MDR1 gene: A possible link between environmental and genetic factors in Parkinson's disease

Pharmacogenetics

Volumn 13, Issue 5, 2003, Pages 259-263

  Droździk, Marek ^a   Białecka, Monika ^a   Myśliwiec, Katarzyna ^a   Honczarenko, Krystyna ^a   Stankiewicz, Jan ^b   Sych, Zbigniew ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Department of General and Transplantation Surgery   (Poland)

Author keywords

MDR1; P glycoprotein; Parkinson's disease; Polymorphism

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PESTICIDE;

ADULT; AGED; ALLELE; ARTICLE; BLOOD BRAIN BARRIER; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG TRANSPORT; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; FEMALE; GENE MUTATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE;

BASE SEQUENCE; DNA PRIMERS; ENVIRONMENT; GENES, MDR; GENOTYPE; HETEROZYGOTE DETECTION; HUMANS; P-GLYCOPROTEIN; PARKINSON DISEASE; POLAND; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 0038241171     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200305000-00004     Document Type: Article

References (18)

1. Markopoulou K, Langston JW. Candidate genes and Parkinson's disease, Where next? Neurology 1999; 53:1382-1383.
2. Tan EK, Khjavi M, Thornby JI, Nagamitsu S, Jankoviv J, Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 2000; 55:533-538.
3. Bialecka M, Gawronska-Szklarz B, Drozdzik M, Honczarenko K, Stankiewicz J. N-acetyltransferase 2 polymorphism in sporadic Parkinson's disease in a Polish population. Eur J Clin Pharmacol 2002; 57:857-862.
4. De Palma G, Mozzoni P, Mutti A, Calzetti S, Negrotti A. Case-control study of interactions between genetic and environmental factors in Parkinson's disease. Lancet 1998; 352:1986-1987.
5. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998; 50:1346-1350.
6. Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, et al. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997; 48:1583-1588.
7. Schinkel AH, Smit JM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemetr L, et al. Disruption of the mouse mdr1 a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77:491-502.
8. Lankas GR, Cartwright ME, Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 1997; 143:357-365.
9. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000; 22:137-140.
10. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97:2517-2524.
11. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-3478.
12. Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002; 12:529-534.
13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17:427-442.
14. Cascorbi I, Gerloff TH, Johne A, Meisel CH, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69:169-174.
15. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression of p-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297:1137-1143.
16. Tanner CM. Parkinson's disease. In: Goreliek PB, Alter M (editors): Handbook of Neuroepidemiology. New York: Marcel Dekker; 1994, pp. 253-280.
17. Le Couteur DG, Davis MW, Webb M, Board PG. P-glycoprotein, multidrug-resistance-associated protein and Parkinson's disease. Eur Neurol 2001; 45:289-290.
18. Schaeffler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001; 358:383-384.